Giazo Alternatives Compared
| Giazo (balsalazide) | Entyvio (vedolizumab) | Ustekinumab |
|
|---|
| Giazo (balsalazide) | Entyvio (vedolizumab) | Ustekinumab |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Ulcerative Colitis - Active, Ulcerative Colitis. Giazo may also be used for purposes not listed in this medication guide. |
Prescription only
Entyvio infusion is an integrin receptor antagonist that may be used to reduce inflammation associated with moderate to severe ulcerative colitis or Crohn's disease. It targets the gut specifically... View more |
Prescription only
Prescribed for Crohn's Disease - Active, Crohn's Disease, Psoriasis, Plaque Psoriasis, Psoriatic Arthritis, Ulcerative Colitis, Ulcerative Colitis - Active. Ustekinumab may also be used for purposes... View more |
Related suggestions Ulcerative Colitis
|
|||||||
| More about Giazo (balsalazide) | More about Entyvio (vedolizumab) | More about Ustekinumab | ||||||||
| Ratings & Reviews | ||||||||||
|
Be the first to share your experience with this drug. |
Entyvio has an average rating of 6.2 out of 10 from a total of 158 ratings on Drugs.com. 49% of reviewers reported a positive effect, while 28% reported a negative effect. |
Ustekinumab has an average rating of 7.5 out of 10 from a total of 261 ratings on Drugs.com. 69% of reviewers reported a positive effect, while 17% reported a negative effect. |
||||||||
| Drug Class | ||||||||||
| Side Effects | ||||||||||
| Generic Availability | ||||||||||
| Lower cost generic approved |
N/A |
N/A |
||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Entyvio prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms Available | ||||||||||
|
|
N/A |
||||||||
| Brand Names | ||||||||||
| Other balsalazide brands include: Colazal | Other vedolizumab brands include: Entyvio Pen | Imuldosa, Otulfi, Pyzchiva, Selarsdi, Stelara, Wezlana, Yesintek | ||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||
|
N/A |
600 hours |
1291.2 hours |
||||||||
| CSA Schedule ** View glossary of terms | ||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | ||||||||||
|
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | ||||||||||
|
A total of 171 drugs are known to interact with Giazo:
|
A total of 158 drugs are known to interact with Entyvio:
|
A total of 525 drugs are known to interact with Ustekinumab:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | ||||||||||
| First Approval Date | ||||||||||
|
N/A |
May 20, 2014 |
September 25, 2009 |
||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| More Information | ||||||||||
| Patient resources | ||||||||||
| Professional Resources | ||||||||||
|
N/A |
||||||||||
| Related Treatment Guide | ||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.